SynthesisZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2016
[Meta-analysis of anti-GP210 antibody and anti-SP100 antibody detection for diagnosis of primary biliary cirrhosis].
Synthesis in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 2 citations in OpenAlex.
- Expression of concern: Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis.PloS one · 2026Article
- Patients with AMA/anti-sp100/anti-gp210 Positivity and Cholestasis Can Manifest Conditions Beyond Primary Biliary Cholangitis.Journal of clinical and translational hepatology · 2025Article
- Diagnostic and Prognostic Value of Monocyte-to-Lymphocyte Ratio and Red Cell Distribution Width to Lymphocyte Ratio in Primary Biliary Cholangitis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Article
- Aberrant cytokeratin 7 expression by hepatocytes can predict the ductopenia grade in primary biliary cholangitis.BMC gastroenterology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo conduct a systematic review of studies assessing the association of anti-GP210 antibody and anti-SP100 antibody with diagnosis of primary biliary cirrhosis (PBC) using meta-analysis.
methodsFive research literature databases, including the Cochrane Library, MEDLINE, VIP, CNKI and WanFang, were searched for studies of anti-GP210 antibody and anti-SP100 antibody in diagnosis of PBC. Meta-disc statistical software was used for analysis.
resultsThe meta-analysis included a total of 25 studies on anti-GP210 antibody and 21 studies on anti-SP100 antibody. The diagnostic odds ratio, sensitivity, and specificity of anti-GP210 antibody for diagnosis of PBC were 24.854 (11.957-51.660), 0.272 (0.257-0.288), and 0.985 (0.982-0.988), respectively, and for anti-SP100 antibody they were 9.133 (4.739-17.600), 0.231 (0.213-0.249), and 0.977 (0.973-0.981), respectively.
conclusionsBoth anti-GP210 antibody and anti-SP100 antibody show high specificity but low sensitivity in diagnosis of PBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.